Targeting WNT/-Catenin via Modulating EZH2 Function: A New Chapter in the Treatment of -Catenin Mutant Hepatocellular Carcinoma?

In a recent study, Rialdi and colleagues identified a specific vulnerability in beta-catenin mutant hepatocellular carcinoma (HCC) via EZH2-mediated suppression of WNT signaling and revealed the selective anti-HCC activity of WNTinib, a chemical derivative of regorafenib and sorafenib in targeting this vulnerability. Their discoveries highlight the role of EZH2 in modulating WNT signaling and suggest an implication of WNTinihb as a small-molecule inhibitor for the treatment of HCC with activated WNT/beta-catenin.